Clinical Trial Update: Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 preoperative trial of atezolizumab (MPDL3280A) in transitional cell carcinoma of the bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Queen Mary University of London | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED